RxDoctor Payments Data

Mark Karabajakian, DO

Cardiovascular Disease · Milford, MINPI 1578571501

Payments from drug & device makers

$3,856in general payments, 2019–2025

Across 231 payments — averaging $16.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$706
  • Merck$630
  • Amarin Pharma, Inc.$359
  • Johnson & Johnson$266
  • AstraZeneca$265
  • E.r. Squibb & Sons, L.L.C.$223
  • plus $1K from 18 others

What the payments were for

  • Food & beverage$3,73397%
  • Education$1233%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,856 in reported general payments places this provider in the 50th percentile of 760 cardiovascular disease providers in Michigan.

See all cardiovascular disease providers in Michigan

Medicare billing

Part B allowed, 2024
$379,666
Medicare patients
1,109
Services billed
4,443

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban164$214,254
EntrestoSacubitril/Valsartan75$90,572
XareltoRivaroxaban57$58,567
MultaqDronedarone Hcl13$26,971
Repatha SureclickEvolocumab19$15,548
BrilintaTicagrelor24$14,052
Repatha SyringeEvolocumab13$12,507
JardianceEmpagliflozin12$12,415
Nitroglycerin272$2,792
Atorvastatin Calcium171$2,468
Valsartan80$2,444
Isosorbide Mononitrate ErIsosorbide Mononitrate131$2,415
Ranolazine ErRanolazine18$2,370
Metoprolol Succinate104$2,011
Rosuvastatin Calcium93$1,582

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$211$214,254164 claims
NovartisEntresto$706$90,57275 claims
Johnson & JohnsonXarelto$266$58,56757 claims
Sanofi-aventis U.S. LLCMultaq$223$26,97113 claims
AstraZenecaBrilinta$265$14,05224 claims
Boehringer IngelheimJardiance$100$12,41512 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 760 cardiovascular disease providers in Michigan.

Other cardiovascular disease in Milford

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →